
Roche acquires Telavant Holdings to win TLA1 race
The takeover of Telavant, a 75:25 jont-venture of Roivant Sciences and the US pharmaceutical group Pfizer, however, may cost Roche up to US-$7.25bn....

CPHI: Trends shaping pharma's path
Despite challenges such as funding slowdowns for biotechs and concerns about high inflation, the industry remains cautiously optimistic,...

$30m for genetic medicine advancements
Eligo Bioscience SA has secured $30m in a series B funding round led by Sanofi Ventures. The funding includes support from new investor Bpifrance, a...

Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

UK boosts AMR defenses with £30m PACE initiative
By bringing together funding, resources, and partnerships from its three notable partners Innovate UK, LifeArc, and Medicines Discovery Catapult...

Spain set to unveil the potential of the biologisation of medicine and food production
At BioSpain 2023, several panels discussed the Spanish EU Presidency's goal of setting the course for the internationally competitive use of...